These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 8977258)

  • 1. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models.
    Lindhofer H; Menzel H; Günther W; Hültner L; Thierfelder S
    Blood; 1996 Dec; 88(12):4651-8. PubMed ID: 8977258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
    Demanet C; Brissinck J; De Jonge J; Thielemans K
    J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation.
    Demanet C; Brissinck J; De Jonge J; Thielemans K
    Blood; 1996 May; 87(10):4390-8. PubMed ID: 8639800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
    Haagen IA
    Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibody-mediated cytotoxicity by CD4+ and CD8(+)-activated T cells generated from leukemia patients after allogeneic bone marrow transplantation.
    Hattori K; Tsukamoto H; Ohta S; Yabe M; Yabe H; Kato S; Takakura I; Ueda R; Habu S; Nishimura T
    Bone Marrow Transplant; 1995 Feb; 15(2):193-8. PubMed ID: 7773208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome.
    Honeychurch J; Cruise A; Tutt AL; Glennie MJ
    Cancer Immunol Immunother; 1997; 45(3-4):171-3. PubMed ID: 9435866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibody treatment of murine B cell lymphoma.
    De Jonge J; Heirman C; De Veerman M; Van Meirvenne S; Demanet C; Brissinck J; Thielemens K
    Cancer Immunol Immunother; 1997; 45(3-4):162-5. PubMed ID: 9435864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
    Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma.
    Haagen IA; Geerars AJ; de Lau WB; Clark MR; van de Griend RJ; Bast BJ; de Gast BC
    Blood; 1994 Jul; 84(2):556-63. PubMed ID: 7517719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
    Demanet C; Brissinck J; Leo O; Moser M; Thielemans K
    Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies.
    De Gast GC; Van Houten AA; Haagen IA; Klein S; De Weger RA; Van Dijk A; Phillips J; Clark M; Bast BJ
    J Hematother; 1995 Oct; 4(5):433-7. PubMed ID: 8581381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
    Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
    Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary metastases neutralization and tumor rejection by in vivo administration of beta glucan and bispecific antibody.
    Penna C; Dean PA; Nelson H
    Int J Cancer; 1996 Jan; 65(3):377-82. PubMed ID: 8575861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation.
    Min CK; Maeda Y; Lowler K; Liu C; Clouthier S; Lofthus D; Weisiger E; Ferrara JL; Reddy P
    Blood; 2004 Nov; 104(10):3393-9. PubMed ID: 15280194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
    Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
    Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
    Haagen IA; Geerars AJ; de Lau WB; Bast BJ; de Gast BC
    Blood; 1995 Jun; 85(11):3208-12. PubMed ID: 7538821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3+CD56+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells.
    Flieger D; Kufer P; Beier I; Sauerbruch T; Schmidt-Wolf IG
    Cancer Immunol Immunother; 2000 Oct; 49(8):441-8. PubMed ID: 11043851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells.
    Arndt C; Feldmann A; Töpfer K; Koristka S; Cartellieri M; Temme A; Ehninger A; Ehninger G; Bachmann M
    Prostate; 2014 Sep; 74(13):1347-58. PubMed ID: 25053504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.